Where does Biomarin Pharmaceutical Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Biomarin Pharmaceutical Inc. ranks #4,183 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Biomarin Pharmaceutical Inc. hold?

Biomarin Pharmaceutical Inc. holds 85 US utility patents granted between 2015 and 2025, spanning 18 technology areas.

What is Biomarin Pharmaceutical Inc.'s Innovation Score?

Biomarin Pharmaceutical Inc. has an Innovation Score of 45.8 out of 100 (top 22% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Biomarin Pharmaceutical Inc.'s patent grant rate increasing or decreasing?

Biomarin Pharmaceutical Inc.'s recent grant velocity is -41% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Biomarin Pharmaceutical Inc.'s patents?

Biomarin Pharmaceutical Inc.'s patents average 18.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Biomarin Pharmaceutical Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Biomarin Pharmaceutical Inc.

Q: What technology areas does Biomarin Pharmaceutical Inc. focus on?

Biomarin Pharmaceutical Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 68 patents. Grants appear in 18 CPC subclasses total.

USPTO PatentsView assignee record - 85 granted patents across 18 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Biomarin ranks #4,183 of 49,997 tracked US assignees by granted-patent volume, with 85 patents across 18 technology areas.

#4,183
of 49,997 US assignees by volume: Top 22%
by Innovation Score (45.8/100): 18.8
avg claims per patent: -41%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4183 · US Corporation #4,183 · 85 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 85 grants
TOP-DECILE #4,183/49,997
PHOTO-FINISH Arlanxeo Deutschland
CPC-FOCUS A61P · 18 areas
INNOV-PAR 45.8/100
CLAIMS-RICH 18.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -41% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Arlanxeo Deutschland GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Biomarin Pharmaceuti… · this assignee

46
Hunter Fan · near

46
Leybold · near

46
Miba Sinter Austria · near

46
Unity IPR ApS · near

46
3D Lighting… · lowest

7

What this shows Biomarin's Innovation Score is 45.8/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Biomarin's grants concentrate

Biomarin Pharmaceutical Inc. is a focused PatentsView assignee: 18 CPC subclasses with 80% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (14 grants) versus a trough of 3 in 2024. By volume, Biomarin sits between Arlanxeo Deutschland GmbH and Chemetall GMBH.

Biomarin's three-year grant acceleration

From 2019–2021 to 2022–2024, Biomarin Pharmaceutical Inc. moved from 27 to 17 grants (0.63x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Arlanxeo Deutschl…

85
Arthrocare

85
Avalara

85
Beijing Jingdong…

85
Boehringer Ingelh…

85
Bitdefender IPR M…

85
Changzhou Univers…

85
Chemetall

85
Biomarin Pharmace… ◀

85

What this shows Biomarin holds 85 patents at rank #4,183, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Biomarin

By rank, the assignees closest to #4,183 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Biomarin's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Biomarin, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (46 here).

Unity IPR ApS 46 Miba Sinter Austria GmbH 46 Hunter Fan Company 46 Leybold GmBH 46

Similar claim depth

Nearest assignees by average claims per patent (18.8 here).

Mujin, Inc. 18.8 avg TE Connectivity Solutions GmbH 18.8 avg Nuvasive Specialized Orthopedics, Inc. 18.8 avg Essential Products, Inc. 18.8 avg

Biomarin's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Biomarin Pharmaceutical Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	10	11.8%
2016	7	8.2%
2017	12	14.1%
2018	8	9.4%
2019	14	16.5%
2020	9	10.6%
2021	4	4.7%
2022	9	10.6%
2023	5	5.9%
2024	3	3.5%
2025partial year	4	4.7%

Which technologies does Biomarin Pharmaceutical Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 68

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 56

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 37

C12Y - Enzymes 29

C07K - Peptides 24

C07D - Heterocyclic Compounds 22

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 20

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 15

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 5

Y02A - Technologies FOR Adaptation TO Climate Change 5

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

A61B - DIAGNOSIS; SURGERY; Identification 3

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 3

C07C - Acyclic OR Carbocyclic Compounds 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 2

Top 15 of 18 technology areas

Where it ranks

Overall rank by patents

#4,183

of 49,997 tracked assignees

Innovation Score

45.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Biomarin Pharmaceutical Inc.'s patent record in context - here's where to go next.

Biomarin Pharmaceutical Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,183 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Biomarin Pharmaceutical Inc. against Arlanxeo Deutschland GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.